Evidence map›Paper›PMID 36628568›Full record

ArticleEpidemiology and infection2023

Hepatitis B burden and population immunity in a high endemicity city - a geographically random household epidemiology study for evaluating achievability of elimination.

Ngai Sze Wong, Denise Pui Chung Chan, Chin Man Poon, Chin Pok Chan, Leonia Hiu Wan Lau, Eng-Kiong Yeoh, Shui Shan Lee

Erratum issuedAbstract read
In one paragraph

Article in Epidemiology and infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Ngai Sze WongStanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0003-3788-8114
Denise Pui Chung ChanStanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China.
Chin Man PoonStanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China.
Chin Pok ChanJC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Leonia Hiu Wan LauJC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Eng-Kiong YeohJC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Shui Shan LeeStanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0003-1448-765X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to provide reference for evaluating the achievability of hepatitis B virus (HBV) elimination in a high endemicity city with universal neonatal vaccination in place for over 30 years. Between September 2018 and October 2020, 2085 citizens from 1143 geographically random households in Hong Kong completed a questionnaire and had blood-testing for HBV markers (anti-HBs, HBsAg, anti-HBc, HBeAg). We evaluated the epidemiology and examined factors associated with HBV exposure, vaccination and chronic diseases. The proportion of households with HBsAg positive index participants was 9.2% (95% CI 7.5%-10.9%). The age- and sex-adjusted HBsAg prevalence was 6.3% (95% CI 5.3%-7.4%), compared to >10% in those born in 1960-1970 and among non-local born citizens, and <1% in people born after introduction of neonatal vaccination. Among 155 HBsAg positive participants, 59% were aware of their infection status with 10% on treatment and 10/150 (6.7%) HBeAg positive. More than 40% (872/2064) tested negative for both HBsAg and anti-HBs, contributed by the lack of immunity in older adults and the waning immunity of vaccines. Hong Kong has remained at high-intermediate HBV endemicity state. The moderate level of anti-HBs positivity and very low treatment coverage (10%) among HBsAg positive participants pose challenges for achieving the HBV elimination target.

Indexed as

Hepatitis BHepatitis B Surface AntigensAgedHepatitis B AntibodiesHepatitis B e AntigensHepatitis B VaccinesHepatitis B virusHumansInfant, NewbornMiddle AgedHepatitis B AntibodiesHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B VaccinesHBV elimination targethepatitis Bpopulation-basedprevalencevaccination

Identifiers

PMID36628568
PMCPMC9990397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.